Felipe Batalini, MD, and Alberto Montero, MD, MBA, CPHQ, detail how allosteric inhibitors targeting PIK3CA such as STX-478 may reduce toxicities seen with orthosteric inhibitors.
Elacestrant was partnered with multiple targeted agents across varying dose levels and schedules for patients with estrogen receptor–positive advanced breast cancer.
Full of stamina and determination, Lynn Lippert supported others and did what she loved through 24 years of living with metastatic breast cancer. Lippert’s life…
Art remains a vital part of Fox Chase Cancer Center’s culture. From the symbolic sculpture, The Diamond, greeting visitors outside the main entrance to the…
Thomas W. LeBlanc, MD, MA, discusses how the standard of care (SOC) options for anemia management in patients with low-risk myelodysplastic syndromes (LR-MDS) typically involve…
Results of the EA4151/BMT-CTN 1601 trial showed similar progression-free and overall outcomes with the addition of autologous transplant to rituximab in mantle cell lymphoma.
Pancreatic cancer survival rates have more than doubled in the past decade. It’s not because of a single breakthrough, but better knowledge of the cancer,…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
By W. Kimryn Rathmell Director, National Cancer Institute Dr.
$50,000 over one year for researchers that seek to stimulate creative approaches to translate basic research into new treatment options for kidney cancer.
